Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effects

IntroductionInflammatory bowel disease (IBD) is a complex immune-mediated condition, and biologics are the most commonly used drugs for its treatment. However, there are still cases of ineffective treatment. B-cell lymphoma 6 (Bcl6), a transcriptional suppressor, is known to have regulatory effects...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruixian Liu, Zhe Zhang, Chuan Zhou, Binbin Wang, Muhan Zhang, Yaxing Sun, Yao Yao, Yanru Zhang, Yijia He, Junzhi Yu, Yimeng Xia, Yan Liu, Shiyang Ning, Baisui Feng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1558845/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850190453432909824
author Ruixian Liu
Zhe Zhang
Chuan Zhou
Binbin Wang
Muhan Zhang
Yaxing Sun
Yao Yao
Yanru Zhang
Yijia He
Junzhi Yu
Yimeng Xia
Yan Liu
Shiyang Ning
Baisui Feng
author_facet Ruixian Liu
Zhe Zhang
Chuan Zhou
Binbin Wang
Muhan Zhang
Yaxing Sun
Yao Yao
Yanru Zhang
Yijia He
Junzhi Yu
Yimeng Xia
Yan Liu
Shiyang Ning
Baisui Feng
author_sort Ruixian Liu
collection DOAJ
description IntroductionInflammatory bowel disease (IBD) is a complex immune-mediated condition, and biologics are the most commonly used drugs for its treatment. However, there are still cases of ineffective treatment. B-cell lymphoma 6 (Bcl6), a transcriptional suppressor, is known to have regulatory effects on multiple immune-associated cell subsets. FX1, a novel specific BCL6 Bric-à-brac (BTB) inhibitor, has shown positive effects in many disease models, but its effects and mechanisms in IBD control remain unclear.MethodsWe observed colon length and DAI score of colitis mice after treatment. HE staining section was used to evaluate colonic injury, while the expression of colonic pro-inflammatory cytokines by RT-qPCR. And differences in immune cell subsets between the two groups was analyzed by flow cytometry. Additionally, IHC and RT-qPCR were employed to evaluate the expression of colonic tight junction proteins. Furthermore, RAW264.7 cells and co-cultured Caco2 cells were detected by ELISA and RT-qPCR.ResultsIn the treat group, colitis symptoms in mice were significantly improved, and there was a decrease in proportion of macrophages and protection of intestinal mucosal integrity-indicating anti-inflammatory effects of FX1. In cell experiments, we found that FX1 decreased secretion of pro-inflammatory factors by macrophages and increased expression of tight junction proteins in Caco2 cells after co-culture.DiscussionThe experimental findings demonstrate the inhibitory effect of FX1 on inflammation in murine colitis model as well as its potential mechanism. BCL6 is a potential target for treating IBD.
format Article
id doaj-art-06aaadbb3afd4d1b8587fbe9905ccb03
institution OA Journals
issn 1664-3224
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-06aaadbb3afd4d1b8587fbe9905ccb032025-08-20T02:15:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15588451558845Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effectsRuixian LiuZhe ZhangChuan ZhouBinbin WangMuhan ZhangYaxing SunYao YaoYanru ZhangYijia HeJunzhi YuYimeng XiaYan LiuShiyang NingBaisui FengIntroductionInflammatory bowel disease (IBD) is a complex immune-mediated condition, and biologics are the most commonly used drugs for its treatment. However, there are still cases of ineffective treatment. B-cell lymphoma 6 (Bcl6), a transcriptional suppressor, is known to have regulatory effects on multiple immune-associated cell subsets. FX1, a novel specific BCL6 Bric-à-brac (BTB) inhibitor, has shown positive effects in many disease models, but its effects and mechanisms in IBD control remain unclear.MethodsWe observed colon length and DAI score of colitis mice after treatment. HE staining section was used to evaluate colonic injury, while the expression of colonic pro-inflammatory cytokines by RT-qPCR. And differences in immune cell subsets between the two groups was analyzed by flow cytometry. Additionally, IHC and RT-qPCR were employed to evaluate the expression of colonic tight junction proteins. Furthermore, RAW264.7 cells and co-cultured Caco2 cells were detected by ELISA and RT-qPCR.ResultsIn the treat group, colitis symptoms in mice were significantly improved, and there was a decrease in proportion of macrophages and protection of intestinal mucosal integrity-indicating anti-inflammatory effects of FX1. In cell experiments, we found that FX1 decreased secretion of pro-inflammatory factors by macrophages and increased expression of tight junction proteins in Caco2 cells after co-culture.DiscussionThe experimental findings demonstrate the inhibitory effect of FX1 on inflammation in murine colitis model as well as its potential mechanism. BCL6 is a potential target for treating IBD.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1558845/fullBCL6IBDpro-inflammatory cytokinesmacrophagetight junction proteins (TJPs)
spellingShingle Ruixian Liu
Zhe Zhang
Chuan Zhou
Binbin Wang
Muhan Zhang
Yaxing Sun
Yao Yao
Yanru Zhang
Yijia He
Junzhi Yu
Yimeng Xia
Yan Liu
Shiyang Ning
Baisui Feng
Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effects
Frontiers in Immunology
BCL6
IBD
pro-inflammatory cytokines
macrophage
tight junction proteins (TJPs)
title Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effects
title_full Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effects
title_fullStr Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effects
title_full_unstemmed Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effects
title_short Inhibitior of Bcl6 by FX1 protects DSS induced colitis mice through anti-inflammatory effects
title_sort inhibitior of bcl6 by fx1 protects dss induced colitis mice through anti inflammatory effects
topic BCL6
IBD
pro-inflammatory cytokines
macrophage
tight junction proteins (TJPs)
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1558845/full
work_keys_str_mv AT ruixianliu inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT zhezhang inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT chuanzhou inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT binbinwang inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT muhanzhang inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT yaxingsun inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT yaoyao inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT yanruzhang inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT yijiahe inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT junzhiyu inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT yimengxia inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT yanliu inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT shiyangning inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects
AT baisuifeng inhibitiorofbcl6byfx1protectsdssinducedcolitismicethroughantiinflammatoryeffects